Chrontech Pharma AB Release: Sale of Hepatitis Technologies Completed
7/22/2013 9:09:38 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ChronTech has now closed the deal concerning the sale of its hepatitis
technologies to the Irish company Avac Pharma Ltd in accordance with the Term
Sheet previously published. This means that the Company has received another
625,000 USD, that the earlier loan of 625,000 USD has been assigned, another 1
million USD will be paid within a year, and that Avac Pharma Ltd will pay up to
1.5 million USD for the further development of ChronTechs injection technology
IVIN. In accordance with the Term Sheet also 80,274,295 shares have been
transferred to ChronTechs certified advisor Remium and the redemption of these
shares have been registered with the Swedish Companies Registration Office.
Help employers find you! Check out all the jobs and post your resume.
comments powered by